Clinical Trial Results:
A prospective, randomized, single-blind, placebo-controlled, two-armed, phase IV study in patients with subclinical hypothyroidism treated over 52 weeks either with levothyroxine in adjusted dosing to a serum TSH target value of 1,0 mU/L +/- 0,5 mU/L or with placebo in the control group.
Summary
|
|
EudraCT number |
2010-023509-37 |
Trial protocol |
DE |
Global completion date |
|
Paediatric regulatory details
|
|
Is the trial part of an agreed EMA paediatric investigation plan? |
|
Is the trial in scope of article 45 of Regulation (EC) No 1901/2006? |
|
Is the trial in scope of article 46 of Regulation (EC) No 1901/2006? |
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
04 Dec 2021
|
First version publication date |
04 Dec 2021
|
Other versions |
|
Summary report(s) |
Document on results |
Note: The legislation allows summary attachments to be posted instead of the full dataset for this trial. Refer to Commission Guideline 2012/C 302/03
for further information.